Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Frequently asked questions
What sector does Milestone Pharmaceuticals Inc (MIST) operate in?
Milestone Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Milestone Pharmaceuticals Inc (MIST) current stock price?
As of the latest data, Milestone Pharmaceuticals Inc stock price is $1.10, with a previous close of $1.10.
What is Milestone Pharmaceuticals Inc (MIST) current market capitalization?
Milestone Pharmaceuticals Inc market cap is approximately 136.95 million.
What is Milestone Pharmaceuticals Inc (MIST) Earnings Per Share (EPS)?
The trailing EPS is -$0.65, and the forward EPS is -$0.78.
What is Milestone Pharmaceuticals Inc (MIST) EBITDA?
Milestone Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -23.83 million.
Does Milestone Pharmaceuticals Inc (MIST) pay dividends?
No. Milestone Pharmaceuticals Inc does not pay a dividend.
How did Milestone Pharmaceuticals Inc (MIST) perform in its most recent earnings report?
In the last report (June 30, 2026), Milestone Pharmaceuticals Inc posted an EPS surprise of -16.67% and a revenue surprise of -31.55%.
What is Milestone Pharmaceuticals Inc (MIST) beta (volatility) score?
Milestone Pharmaceuticals Inc has a beta of 0.977, meaning its volatility is roughly in line with the market.
